{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:38:36Z","timestamp":1785577116848,"version":"3.56.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1678,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031829","name":"Ceva Sant\u00e9 Animale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The renin-angiotensin-aldosterone system (RAAS), when chronically activated, is harmful and RAAS-suppressive drugs are beneficial in the treatment of congestive heart failure (CHF). Mineralocorticoid receptor antagonists are widely used in the treatment of CHF in people.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>To determine if a mineralocorticoid receptor antagonist (spironolactone) is beneficial and safe in CHF due to myxomatous mitral valve disease (MMVD) of varying severity, we hypothesized that, when combined with furosemide, a combination product (S+BNZ) containing the ACE inhibitor (ACE-I), benazepril, and spironolactone, would be superior to benazepril alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Five hundred and sixty-nine client-owned dogs, with MMVD and CHF (ACVIM Stage C) of \u226410-days' duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>After initial stabilization, dogs were randomized into a positive-controlled, double-blind, multicenter trial, to receive furosemide plus S+BNZ or furosemide plus benazepril. The primary outcome variable was the percentage of dogs reaching cardiac endpoint before Day 360. Cardiac endpoint was defined as cardiac death or euthanasia, recurrence of pulmonary edema, necessity for nonauthorized cardiac drug(s) or a furosemide dosage &amp;gt;8\u00a0mg\/kg\/d.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A significantly lower percentage of dogs treated with S+BNZ reached the primary outcome variable by Day 360 (OR\u00a0=\u00a00.56; 95% CI, 0.32-0.98; P\u00a0=\u00a0.04) and risk of dying or worsening from cardiac causes, was significantly reduced (HR\u00a0=\u00a00.73; 95% CI\u00a0=\u00a00.59-0.89, P\u00a0=\u00a0.002) vs benazepril alone. Adverse events, potentially associated with treatment, were rare and equal between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Clinical Importance<\/jats:title>\n                    <jats:p>The combination of S+BNZ is effective, safe, and superior to benazepril alone, when used with furosemide for the management of mild, moderate or severe CHF caused by MMVD in dogs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.16155","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T07:54:30Z","timestamp":1621842870000},"page":"1673-1687","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST)"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6156-6484","authenticated-orcid":false,"given":"Melissa","family":"Coffman","sequence":"first","affiliation":[{"name":"Pharmaceutical Innovation & Development, Ceva Animal Health , Lenexa, Kansas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6892-4176","authenticated-orcid":false,"given":"Emilie","family":"Guillot","sequence":"additional","affiliation":[{"name":"Companion Animal Franchise, Ceva Sant\u00e9 Animale , Libourne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6316-967X","authenticated-orcid":false,"given":"Thomas","family":"Blondel","sequence":"additional","affiliation":[{"name":"Innovation & Development, Ceva Sant\u00e9 Animale , Libourne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Garelli-Paar","sequence":"additional","affiliation":[{"name":"Companion Animal Franchise, Ceva Sant\u00e9 Animale , Libourne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Feng","sequence":"additional","affiliation":[{"name":"Innovation & Development, Ceva Biomune , Lenexa, Kansas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7315-3927","authenticated-orcid":false,"given":"Susanne","family":"Heartsill","sequence":"additional","affiliation":[{"name":"Veterinary Services, Ceva Animal Health , Lenexa, Kansas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4463-4625","authenticated-orcid":false,"given":"Clarke E.","family":"Atkins","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, North Carolina State University Department of Clinical Sciences, , Raleigh, North Carolina,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"2026020922170889100_jvim16155-bib-0001","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/jvim.15454","article-title":"The renin-angiotensin-aldosterone system and its suppression","volume":"33","author":"Ames","year":"2019","journal-title":"J Vet Intern Med"},{"key":"2026020922170889100_jvim16155-bib-0002","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"2026020922170889100_jvim16155-bib-0003","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"4","key":"2026020922170889100_jvim16155-bib-0004","first-page":"1787","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"2026020922170889100_jvim16155-bib-0005","first-page":"e240","article-title":"2013 ACCF\/AHA guidelines for the management of heart failure","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"2026020922170889100_jvim16155-bib-0006","first-page":"891","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)","volume":"8","author":"Ponikowski","year":"2016","journal-title":"Euro J Cardiol"},{"key":"2026020922170889100_jvim16155-bib-0007","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2026020922170889100_jvim16155-bib-0008","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1939-1676.2009.0467.x","article-title":"Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease","volume":"24","author":"Bernay","year":"2010","journal-title":"J Vet Intern Med"},{"key":"2026020922170889100_jvim16155-bib-0009","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jvp.12154","article-title":"Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs","volume":"38","author":"Lantis","year":"2015","journal-title":"J Vet Pharmacol Therap"},{"key":"2026020922170889100_jvim16155-bib-0010","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/jvp.12216","article-title":"The effect of enalapril on furosemide-activated renin-angiotensin-aldosterone system in healthy dogs","volume":"38","author":"Lantis","year":"2015","journal-title":"J Vet Pharmacol Therap"},{"key":"2026020922170889100_jvim16155-bib-0011","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1365-2885.2007.00894.x","article-title":"The effect of amlodipine and the combination of amlodipine and enalapril on the renin-angiotensin-aldosterone system in the dog","volume":"30","author":"Atkins","year":"2007","journal-title":"J Vet Pharmacol Therap"},{"key":"2026020922170889100_jvim16155-bib-0012","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1939-1676.2009.0367.x","article-title":"Acute effects of pimobendan and furosemide on the circulating renin-angiotensin-aldosterone system in healthy dogs","volume":"23","author":"Sayer","year":"2009","journal-title":"J Vet Intern Med"},{"key":"2026020922170889100_jvim16155-bib-0013","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2460\/ajvr.74.8.1084","article-title":"Effect of furosemide and high-dosage pimobendan administration on the renin-angiotensin-aldosterone system in dogs","volume":"74","author":"Ames","year":"2013","journal-title":"Am J Vet Res"},{"key":"2026020922170889100_jvim16155-bib-0014","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2460\/ajvr.76.12.1041","article-title":"Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs","volume":"76","author":"Ames","year":"2015","journal-title":"Am J Vet Res"},{"key":"2026020922170889100_jvim16155-bib-0015","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.2460\/ajvr.72.12.1646","article-title":"Effects of furosemide and the combination of furosemide and the labeled dosage of pimobendan on the circulating renin-angiotensin-aldosterone system in clinically normal dogs","volume":"72","author":"Lantis","year":"2011","journal-title":"Am J Vet Res"},{"issue":"4","key":"2026020922170889100_jvim16155-bib-0016","first-page":"1","article-title":"Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone: creatinine, after pharmacologic provocation) and the response to ACE inhibition","volume":"17","author":"Ames","year":"2016","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2026020922170889100_jvim16155-bib-0017","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jvc.2012.02.002","article-title":"Pharmacologic management of myxomatous mitral valvular disease in dogs","volume":"14","author":"Atkins","year":"2012","journal-title":"J Vet Cardiol"},{"key":"2026020922170889100_jvim16155-bib-0018","first-page":"87","article-title":"Beyond furosemide: the role of diuretics in congestive heart failure part 2 \u2013 spironolactone","volume":"6","author":"Ames","year":"2016","journal-title":"Today's Vet Pract"},{"key":"2026020922170889100_jvim16155-bib-0019","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/jvim.15488","article-title":"Guidelines for the diagnosis and treatment of canine chronic valvular heart disease","volume":"33","author":"Keene","year":"2019","journal-title":"J Vet Intern Med"},{"key":"2026020922170889100_jvim16155-bib-0020","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/j.1939-1676.2009.0392.x","article-title":"Guidelines for the diagnosis and treatment of canine chronic valvular heart disease","volume":"23","author":"Atkins","year":"2009","journal-title":"J Vet Intern Med"},{"key":"2026020922170889100_jvim16155-bib-0021","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.2460\/javma.2005.226.1864","article-title":"Development and evaluation of a questionnaire for assessing health-related quality of life in dogs with cardiac disease","volume":"226","author":"Freeman","year":"2005","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922170889100_jvim16155-bib-0022","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/biomet\/77.1.147","article-title":"Martingale-based residuals for survival models","volume":"77","author":"Therneau","year":"1990","journal-title":"Biometrika"},{"key":"2026020922170889100_jvim16155-bib-0023","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"2026020922170889100_jvim16155-bib-0024","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/bmj.300.6719.230","article-title":"Analysis of serial measurements in medical research","volume":"300","author":"Matthews","year":"1990","journal-title":"Br Med J"},{"key":"2026020922170889100_jvim16155-bib-0025","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026020922170889100_jvim16155-bib-0026","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026020922170889100_jvim16155-bib-0027","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2460\/javma.2002.221.654","article-title":"Effects of long-term administration of enalapril on clinical indicators of renal function in dogs with compensated mitral regurgitation","volume":"221","author":"Atkins","year":"2002","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922170889100_jvim16155-bib-0028","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/jvim.12141","article-title":"Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study","volume":"27","author":"Lefebvre","year":"2013","journal-title":"J Vet Intern Med"},{"key":"2026020922170889100_jvim16155-bib-0029","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jvc.2007.08.002","article-title":"Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg++, and Na+ concentrations in small dogs with degenerative mitral valve disease","volume":"9","author":"Thomason","year":"2007","journal-title":"J Vet Cardiol"},{"key":"2026020922170889100_jvim16155-bib-0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1939-1676.1995.tb01074.x","article-title":"Acute and short-term hemodynamic, echocardiographic clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the invasive multicenter PROspective veterinary evaluation of enalapril study","volume":"9","author":"The IMPROVE Study Group","year":"1995","journal-title":"J Vet Intern Med"},{"key":"2026020922170889100_jvim16155-bib-0031","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1939-1676.1995.tb01075.x","article-title":"Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril study group","volume":"9","author":"The COVE Study Group","year":"1995","journal-title":"J Vet Intern Med"},{"key":"2026020922170889100_jvim16155-bib-0032","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2460\/javma.1998.213.11.1573","article-title":"Effects of enalapril maleate on survival of dogs with naturally occurring acquired heart failure","volume":"213","author":"Ettinger","year":"1998","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922170889100_jvim16155-bib-0033","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1760-2734(06)70025-X","article-title":"The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: results of a multi-center, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial","volume":"1","author":"The BENCH BENazepril in Canine Heart Disease Study Group","year":"1999","journal-title":"J Vet Cardiol"},{"key":"2026020922170889100_jvim16155-bib-0034","first-page":"123","article-title":"Prospective multi-centre, long-term ramipril (Vasotop\u00ae) treatment of dogs with naturally acquired heart failure","volume":"45","author":"Sent","year":"2000","journal-title":"Kleintierpraxis"},{"key":"2026020922170889100_jvim16155-bib-0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1760-2734(06)70053-4","article-title":"Comparison of the effects of imidapril and enalapril in a prospective, multicentric randomized trial in dogs with naturally acquired heart failure","volume":"6","author":"Amberger","year":"2004","journal-title":"J Vet Cardiol"},{"key":"2026020922170889100_jvim16155-bib-0036","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1748-5827.2006.00170.x","article-title":"Clinical evaluation of imidapril in congestive heart failure in dogs: results of the EFFIC study","volume":"48","author":"Besche","year":"2007","journal-title":"J Small Anim Pract"},{"key":"2026020922170889100_jvim16155-bib-0037","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS)","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"key":"2026020922170889100_jvim16155-bib-0038","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1681\/ASN.2016121344","article-title":"How dangerous is hyperkalemia","volume":"28","author":"Montford","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2026020922170889100_jvim16155-bib-0039","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s11095-014-1587-9","article-title":"Pharmacokinetic\/pharmacodynamic modeling of renin-angiotensin aldosterone biomarkers following angiotensin-converting enzyme (ACE) inhibition therapy with benazepril in dogs","volume":"32","author":"Mochel","year":"2015","journal-title":"Pharm Res"},{"key":"2026020922170889100_jvim16155-bib-0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejps.2018.11.037","article-title":"Sacubitril\/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation","volume":"128","author":"Mochel","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"2026020922170889100_jvim16155-bib-0041","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jvc.2018.07.009","article-title":"Evaluation of the inhibitory effects of telmisartan on drug-induced renin-angiotensin-aldosterone system activation in normal dogs","volume":"20","author":"Konta","year":"2018","journal-title":"J Vet Cardiol"},{"key":"2026020922170889100_jvim16155-bib-0042","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2460\/ajvr.1996.57.11.1645","article-title":"Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation","volume":"57","author":"Haggstrom","year":"1996","journal-title":"Am J Vet Res"},{"issue":"4","key":"2026020922170889100_jvim16155-bib-0043","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2460\/ajvr.2001.62.1793","article-title":"Additive effects of a sodium chloride restricted diet and furosemide administration in healthy dogs","volume":"62","author":"Lovern","year":"2001","journal-title":"Am J Vet Res"},{"key":"2026020922170889100_jvim16155-bib-0044","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jvc.2017.03.001","article-title":"Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease","volume":"19","author":"Ames","year":"2017","journal-title":"J Vet Cardiol"},{"key":"2026020922170889100_jvim16155-bib-0045","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/eurheartj\/ehn383","article-title":"Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction","volume":"29","author":"Palmer","year":"2008","journal-title":"Eur Heart J"},{"key":"2026020922170889100_jvim16155-bib-0046","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurjhf\/hft100","article-title":"Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial","volume":"15","author":"Girerd","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026020922170889100_jvim16155-bib-0047","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1939-1676.2008.0150.x","article-title":"Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study","volume":"22","author":"H\u00e4ggstr\u00f6m","year":"2008","journal-title":"J Vet Intern Med"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.16155","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.16155","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/35\/4\/1673\/66652570\/jvim16155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/35\/4\/1673\/66652570\/jvim16155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:26:55Z","timestamp":1770694015000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/35\/4\/1673\/8447036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.16155","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7]]},"published":{"date-parts":[[2021,7,1]]},"assertion":[{"value":"2020-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}